ImmunityBio(IBRX)
Focus: ImmunityBio is a San Diego-based public biotech focused on cellular therapy and immuno-oncology, with a diversified pipeline spanning Phase 1–3 oncology and infectious disease programs. The company operates as a pre-revenue stage entity with minimal commercial traction ($622K FY2025 revenue) and substantial R&D burn.
Profile data last refreshed 44m ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
49+25 this month
Hot — 54 jobs added in 30d
Net +25 (54 new, 29 removed). Aggressive expansion phase.
Should You Work at ImmunityBio?
AI assessmentImmunityBio suits risk-tolerant scientists and regulatory specialists betting on cellular therapy upside, but demands acceptance of near-term cash crisis and recent compliance turbulence.
Why Work Here
- Access to cutting-edge cellular therapy platforms (haNK, CAR-T derivatives, allogeneic MSC) at a formative stage, offering deep technical exposure in an underdeveloped modality.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$622K
Pipeline & Clinical Trials
rMBCG
NMIBCClinical Trials (1)
NCT06810141ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
N/AHelp build intelligence for ImmunityBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.